CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1670115
This article is part of the Research TopicInnovative Biomarkers for Chronic Myeloid Leukemia: Detection, and Therapy.View all 3 articles
A Chronic Myeloid Leukemia Patient with e8a2 BCR::ABL1 Fusion Transcript Was Successfully Treated with Flumatinib: A Case Report
Provisionally accepted
- hematology, Department of Hematology, Tianjin Medical University General Hospital, tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The majority of patients with chronic myeloid leukemia (CML) present with BCR::ABL1 transcripts involving the b2a2 (e13a2) and/or b3a2 (e14a2) junctions. However, a small subset of cases exhibit atypical breakpoints. These atypical BCR::ABL1 transcripts are found in approximately 2% of CML patients. It is essential to identify these atypical variants as they respond to tyrosine kinase inhibitor therapy, similar to patients with the more common transcript types. This report described a CML patient with a rare e8a2 BCR::ABL1 transcript variant, who also presented with difficult-to-correct iron-deficiency anemia. The patient was treated with Flumatinib and achieved complete hematologic remission at 1 month, complete cytogenetic remission at 3 months, and major molecular remission at 6 months.
Keywords: Chronic myeloid leukemia, e8a2 BCR::ABL1 transcript, Flumatinib, iron-deficiencyanemia, Tyrosine kinase inhibitor therapy
Received: 21 Jul 2025; Accepted: 04 Sep 2025.
Copyright: © 2025 Hao, Zhang, Shao and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lijuan Li, hematology, Department of Hematology, Tianjin Medical University General Hospital, tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.